432 related articles for article (PubMed ID: 36755812)
61. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen HM; Guz-Montgomery K; Saha D
Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
[TBL] [Abstract][Full Text] [Related]
62. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
63. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
64. Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Alluqmani N; Jirovec A; Taha Z; Varette O; Chen A; Serrano D; Maznyi G; Khan S; Forbes NE; Arulanandam R; Auer RC; Diallo JS
Front Immunol; 2022; 13():1032356. PubMed ID: 36532027
[TBL] [Abstract][Full Text] [Related]
65. STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells.
Shao X; Wang X; Guo X; Jiang K; Ye T; Chen J; Fang J; Gu L; Wang S; Zhang G; Meng S; Xu Q
Front Oncol; 2019; 9():436. PubMed ID: 31192135
[No Abstract] [Full Text] [Related]
66. Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines.
Niavarani SR; Lawson C; Tai LH
Viruses; 2019 May; 11(5):. PubMed ID: 31083491
[TBL] [Abstract][Full Text] [Related]
67. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
68. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy.
Yu S; Xiao H; Ma L; Zhang J; Zhang J
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188946. PubMed ID: 37385565
[TBL] [Abstract][Full Text] [Related]
69. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
70. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen T; Avci NG; Shin DH; Martinez-Velez N; Jiang H
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857493
[TBL] [Abstract][Full Text] [Related]
71. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
72. Updates to the antitumor mechanism of oncolytic virus.
Bai Y; Hui P; Du X; Su X
Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
[TBL] [Abstract][Full Text] [Related]
73. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang S; Rabkin SD
Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
[No Abstract] [Full Text] [Related]
74. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.
Ma J; Ramachandran M; Jin C; Quijano-Rubio C; Martikainen M; Yu D; Essand M
Cell Death Dis; 2020 Jan; 11(1):48. PubMed ID: 31969562
[TBL] [Abstract][Full Text] [Related]
75. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
[TBL] [Abstract][Full Text] [Related]
76. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
77. Oncolytic viruses and immunity.
Chaurasiya S; Chen NG; Fong Y
Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
[TBL] [Abstract][Full Text] [Related]
78. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
Wang S; Wei J
Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
[TBL] [Abstract][Full Text] [Related]
79. Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy.
Sun M; Yang S; Huang H; Gao P; Pan S; Cheng Z; He Z; Wang Z; Sun J; Liu F
Nano Lett; 2022 Jun; 22(12):5055-5064. PubMed ID: 35583490
[TBL] [Abstract][Full Text] [Related]
80. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
